PDL BioPharma (PDLI) Tops Q4 EPS by 12c, Beats on Revenues

March 8, 2018 4:04 PM

Note: EPS may not be comparable

PDL BioPharma (NASDAQ: PDLI) reported Q4 EPS of $0.15, $0.12 better than the analyst estimate of $0.03. Revenue for the quarter came in at $68 million versus the consensus estimate of $45.3 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

Categories

Earnings Guidance